BioNTech SE - ADR

NASDAQ:BNTX   3:59:59 PM EDT
137.64
+0.45 (+0.33%)
Products

FDA Authorizes Moderna, Pfizer-Biontech Bivalent Covid-19 Vaccines For Use As A Booster Dose

Published: 08/31/2022 13:56 GMT
BioNTech SE - ADR (BNTX) - FDA Authorizes Moderna, Pfizer-biontech Bivalent Covid-19vaccines for Use As a Booster Dose.
FDA - Moderna Covid-19 Vaccine, Bivalent, is Authorized for Use As a Single Booster Dose in Individuals 18 Years of Age and Older.
FDA Says Pfizer-biontech Covid-19 Vaccine, Bivalent, is Authorized for Use As a Single Booster Dose in Individuals 12 Years of Age and Older.
FDA - Pfizer-biontech Covid-19 Vaccine, Bivalent, is Authorized for Use As a Single Booster Dose in Individuals 12 Years of Age and Older.
FDA - With Aug 31 St Authorization, Monovalent Mrna Covid-19 Vaccines Are Not Authorized As Booster Doses for Individuals 12 Years of Age and Older.
FDA - Revised Eua of Moderna Covid-19 Vaccine, Pfizer-biontech Covid-19 Vaccine to Remove Use of Monovalent Moderna for Booster Administration for 18 Years and Older.
FDA - Revised Eua of Pfizer-biontech Covid-19 Vaccine to Remove Use of Pfizer-biontech Covid-19 Vaccines for Booster Administration for 12 Years and Older.
Further Company Coverage: Pfen ((reuters.
Briefs@thomsonreuters.
Com;)).